Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ST-segment elevation myocardial infarction.
Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, Gibson CM, Goto S, Katus HA, Kerneis M, Kimura T, Kunadian V, Pinto DS, Shiomi H, Spertus JA, Steg PG, Mehran R. Vogel B, et al. Among authors: goto s. Nat Rev Dis Primers. 2019 Jun 6;5(1):39. doi: 10.1038/s41572-019-0090-3. Nat Rev Dis Primers. 2019. PMID: 31171787 Review.
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.
Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. Ohman EM, et al. Among authors: goto s. Am Heart J. 2006 Apr;151(4):786.e1-10. doi: 10.1016/j.ahj.2005.11.004. Am Heart J. 2006. PMID: 16569533
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E. Gibson CM, et al. Among authors: goto s. Am Heart J. 2011 May;161(5):815-821.e6. doi: 10.1016/j.ahj.2011.01.026. Am Heart J. 2011. PMID: 21570509 Clinical Trial.
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, Liau CS, Wilson PW, Salette G, Smith SC, Steg PG; REACH Registry Investigators. Meadows TA, et al. Among authors: goto s. Mayo Clin Proc. 2011 Oct;86(10):960-7. doi: 10.4065/mcp.2011.0010. Mayo Clin Proc. 2011. PMID: 21964173 Free PMC article.
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG. Roussel R, et al. Among authors: goto s. Int J Cardiol. 2013 Aug 20;167(4):1380-4. doi: 10.1016/j.ijcard.2012.04.019. Epub 2012 May 4. Int J Cardiol. 2013. PMID: 22560911
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E; ATLAS-ACS 2 TIMI 51 Investigators. Gibson CM, et al. Among authors: goto s. J Am Coll Cardiol. 2013 Jul 23;62(4):286-90. doi: 10.1016/j.jacc.2013.03.041. Epub 2013 Apr 16. J Am Coll Cardiol. 2013. PMID: 23602776 Free article. Clinical Trial.
3,596 results